ONCOPEPTIDES AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.685 SEK | +5.50% |
|
+5.92% | -64.95% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,032 | 11,529 | 632.5 | 1,146 | 724.6 | 577.8 | - | - |
| Enterprise Value (EV) 1 | 6,106 | 10,689 | 441.7 | 801.3 | 657.7 | 417.2 | 505.9 | 397.8 |
| P/E ratio | -8.86 x | -6.64 x | -0.44 x | -2.96 x | -2.78 x | -1.32 x | -2.48 x | -8.72 x |
| Yield | - | - | - | - | - | - | - | 37.2% |
| Capitalization / Revenue | - | - | 5.35 x | 137 x | 20.6 x | 6.87 x | 2.9 x | 1.93 x |
| EV / Revenue | - | - | 3.73 x | 95.9 x | 18.7 x | 4.96 x | 2.54 x | 1.33 x |
| EV / EBITDA | -8.31 x | -6.78 x | -0.32 x | -2.41 x | - | -1.73 x | -2.69 x | -7.21 x |
| EV / FCF | -8.81 x | -8.12 x | -0.29 x | -1.89 x | -2.35 x | -1.98 x | -3.95 x | -8.65 x |
| FCF Yield | -11.4% | -12.3% | -343% | -52.8% | -42.5% | -50.6% | -25.3% | -11.6% |
| Price to Book | 8.82 x | 20 x | 3 x | 3.73 x | 12.2 x | 1.03 x | 2.46 x | - |
| Nbr of stocks (in thousands) | 55,413 | 67,940 | 75,292 | 94,309 | 94,600 | 215,186 | - | - |
| Reference price 2 | 126.9 | 169.7 | 8.400 | 12.15 | 7.660 | 2.685 | 2.685 | 2.685 |
| Announcement Date | 2/20/20 | 2/18/21 | 2/17/22 | 2/16/23 | 2/24/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 118.3 | 8.355 | 35.2 | 84.16 | 199.1 | 300 |
| EBITDA 1 | -734.9 | -1,577 | -1,400 | -332.2 | - | -241 | -187.8 | -55.15 |
| EBIT 1 | -739.4 | -1,591 | -1,421 | -349.4 | -253.4 | -233.8 | -165.5 | -55.33 |
| Operating Margin | - | - | -1,201.16% | -4,181.33% | -719.89% | -277.76% | -83.11% | -18.44% |
| Earnings before Tax (EBT) 1 | -739.9 | -1,592 | -1,421 | -337.7 | -248.4 | -241 | -176 | -69.93 |
| Net income 1 | -740.7 | -1,595 | -1,430 | -338 | -249.1 | -241 | -172.3 | -63.51 |
| Net margin | - | - | -1,209.11% | -4,044.9% | -707.7% | -286.32% | -86.51% | -21.17% |
| EPS 2 | -14.33 | -25.57 | -19.00 | -4.110 | -2.760 | -2.039 | -1.082 | -0.3079 |
| Free Cash Flow 1 | -693.2 | -1,317 | -1,517 | -423 | -279.6 | -211 | -128 | -46 |
| FCF margin | - | - | -1,282.16% | -5,063.03% | -794.34% | -250.73% | -64.28% | -15.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1.000 |
| Announcement Date | 2/20/20 | 2/18/21 | 2/17/22 | 2/16/23 | 2/24/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|
| Net sales 1 | -21.71 | - | 8.753 | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -389.8 | -98.86 | -61.09 | -88.85 |
| Operating Margin | 1,795.65% | - | -697.89% | - |
| Earnings before Tax (EBT) 1 | -389.5 | -98.6 | -59.55 | -88.33 |
| Net income 1 | -394 | -98.59 | -59.83 | -88.44 |
| Net margin | 1,814.79% | - | -683.5% | - |
| EPS 2 | -5.230 | -1.310 | -0.7900 | -1.000 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/17/22 | 5/4/22 | 8/11/22 | 11/9/22 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 926 | 840 | 191 | 345 | 66.9 | 161 | 71.9 | 180 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -693 | -1,317 | -1,517 | -423 | -280 | -211 | -128 | -46 |
| ROE (net income / shareholders' equity) | -139% | -232% | -363% | -134% | -142% | -344% | -119% | -65% |
| ROA (Net income/ Total Assets) | -107% | -164% | -206% | -82% | -79.9% | -73.3% | -45.7% | -16.3% |
| Assets 1 | 693.6 | 970.1 | 693.1 | 412.3 | 311.9 | 328.7 | 376.9 | 389.6 |
| Book Value Per Share 2 | 14.40 | 8.490 | 2.800 | 3.260 | 0.6300 | 2.600 | 1.090 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.63 | 20.1 | 0.34 | 2.51 | 0.12 | 10.5 | 12.9 | - |
| Capex / Sales | - | - | 0.29% | 30.01% | 0.33% | 12.43% | 6.49% | - |
| Announcement Date | 2/20/20 | 2/18/21 | 2/17/22 | 2/16/23 | 2/24/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.685
SEK
Average target price
6.1
SEK
Spread / Average Target
+127.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -64.95% | 52.23M | |
| +20.12% | 127B | |
| +25.25% | 117B | |
| +25.56% | 27.77B | |
| -19.51% | 20.44B | |
| -14.36% | 16.62B | |
| -15.63% | 15.92B | |
| -46.67% | 14.94B | |
| +11.89% | 14.74B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- ONCO Stock
- Financials Oncopeptides AB
